Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Asian Markets Slip as Precious Metals Cool, Geopolitical Tensions Weigh on Sentiment 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
